Regenxbio (NASDAQ:RGNX) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
RGNX has been the topic of a number of other reports. ValuEngine downgraded Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Chardan Capital lifted their price objective on Regenxbio from $75.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Barclays started coverage on Regenxbio in a report on Wednesday, November 22nd. They set an “overweight” rating and a $38.00 price objective on the stock. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Regenxbio presently has a consensus rating of “Buy” and a consensus price target of $42.43.
Shares of Regenxbio (RGNX) opened at $25.70 on Friday. The firm has a market capitalization of $806.71 and a P/E ratio of -9.48. Regenxbio has a 1-year low of $16.30 and a 1-year high of $36.45.
In other news, SVP Curran Simpson sold 30,000 shares of Regenxbio stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $33.03, for a total value of $990,900.00. Following the completion of the transaction, the senior vice president now owns 69,500 shares in the company, valued at $2,295,585. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief financial officer now owns 87,277 shares of the company’s stock, valued at approximately $2,618,310. The disclosure for this sale can be found here. Insiders sold 94,000 shares of company stock valued at $2,879,096 in the last quarter. 17.00% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. RTW Investments LP raised its stake in shares of Regenxbio by 20.9% in the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock valued at $50,710,000 after acquiring an additional 266,235 shares during the last quarter. Perceptive Advisors LLC raised its position in Regenxbio by 5.1% in the 3rd quarter. Perceptive Advisors LLC now owns 1,441,186 shares of the biotechnology company’s stock worth $47,487,000 after purchasing an additional 70,000 shares during the last quarter. JPMorgan Chase & Co. raised its position in Regenxbio by 3.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,270,327 shares of the biotechnology company’s stock worth $40,778,000 after purchasing an additional 43,492 shares during the last quarter. Vanguard Group Inc. raised its position in Regenxbio by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after purchasing an additional 100,944 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in Regenxbio by 62.2% in the 4th quarter. Citadel Advisors LLC now owns 987,752 shares of the biotechnology company’s stock worth $32,843,000 after purchasing an additional 378,612 shares during the last quarter. Institutional investors own 68.71% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.